SI0814782T1 - Pharmaceutical composition stabilized with a basic agent - Google Patents

Pharmaceutical composition stabilized with a basic agent

Info

Publication number
SI0814782T1
SI0814782T1 SI9630566T SI9630566T SI0814782T1 SI 0814782 T1 SI0814782 T1 SI 0814782T1 SI 9630566 T SI9630566 T SI 9630566T SI 9630566 T SI9630566 T SI 9630566T SI 0814782 T1 SI0814782 T1 SI 0814782T1
Authority
SI
Slovenia
Prior art keywords
pharmaceutical composition
basic agent
composition stabilized
composition
stabilized
Prior art date
Application number
SI9630566T
Other languages
English (en)
Slovenian (sl)
Inventor
Toyojiro Muramatsu
Katsumi Mashita
Yasuo Shinoda
Hironori Sassa
Hiroyuki Kawashima
Yoshio Tanizawa
Hideatsu Takeuchi
Original Assignee
Kowa Company, Ltd.
Nissan Chemical Industries, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Company, Ltd., Nissan Chemical Industries, Limited filed Critical Kowa Company, Ltd.
Publication of SI0814782T1 publication Critical patent/SI0814782T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI9630566T 1995-12-22 1996-12-20 Pharmaceutical composition stabilized with a basic agent SI0814782T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP35465495 1995-12-22
PCT/JP1996/003722 WO1997023200A1 (fr) 1995-12-22 1996-12-20 Composition pharmaceutique stabilisee a l'aide d'un agent de base
EP96942588A EP0814782B1 (fr) 1995-12-22 1996-12-20 Composition pharmaceutique stabilisee a l'aide d'un agent de base

Publications (1)

Publication Number Publication Date
SI0814782T1 true SI0814782T1 (en) 2003-04-30

Family

ID=18439011

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9630566T SI0814782T1 (en) 1995-12-22 1996-12-20 Pharmaceutical composition stabilized with a basic agent

Country Status (26)

Country Link
EP (1) EP0814782B1 (fr)
JP (1) JP3276962B2 (fr)
KR (1) KR100348842B1 (fr)
CN (1) CN1137684C (fr)
AT (1) ATE228354T1 (fr)
AU (1) AU725622B2 (fr)
CA (1) CA2213608C (fr)
CZ (1) CZ288545B6 (fr)
DE (2) DE122011000014I1 (fr)
DK (1) DK0814782T3 (fr)
ES (1) ES2183023T3 (fr)
FR (1) FR11C0007I2 (fr)
HU (1) HU227798B1 (fr)
IL (1) IL121565A (fr)
MX (1) MX9706389A (fr)
NO (2) NO316724B1 (fr)
NZ (1) NZ324446A (fr)
PL (1) PL186907B1 (fr)
PT (1) PT814782E (fr)
RU (1) RU2142790C1 (fr)
SI (1) SI0814782T1 (fr)
SK (1) SK282991B6 (fr)
TW (1) TW436294B (fr)
UA (1) UA29513C2 (fr)
WO (1) WO1997023200A1 (fr)
ZA (1) ZA9610792B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5140079A1 (es) * 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
EP1161236A1 (fr) * 1999-03-08 2001-12-12 Merck & Co., Inc. Acide ouvert en dihydroxy et sels d'inhibiteurs de la hmg-co-a reductase
EP1036563A1 (fr) * 1999-03-08 2000-09-20 MERCK & CO. INC. Formulations retard a usage oral de simvastatine sous forme ouverte d'acide dihydroxy, de ses sels ou de ses esters
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
WO2001042218A1 (fr) * 1999-12-13 2001-06-14 Kabushiki Kaisha Toyota Chuo Kenkyusho Derives de quinoleine et dispositifs electroluminescents organiques
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
US6806290B2 (en) 2000-06-09 2004-10-19 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
ATE260101T1 (de) 2000-06-09 2004-03-15 Lek Tovarna Farmacevtskih Stabilisierte pharmazeutisch wirksame zubereitung und diese enthaltende arzneizusammensetzung
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
WO2004026297A1 (fr) * 2002-09-20 2004-04-01 Kowa Co., Ltd. Preparation pour usage externe
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
CN100471835C (zh) 2003-12-23 2009-03-25 默克公司 抗高胆固醇血症化合物
JPWO2005063294A1 (ja) 2003-12-30 2007-12-13 興和株式会社 γ−セクレターゼ複合体形成阻害剤
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
EP1719525B1 (fr) 2004-02-25 2014-12-10 Kowa Company, Ltd. Promoteur de transfert nuclaire pour la proteine cdc42 et methode de criblage pour celle-ci
EP1719524B1 (fr) 2004-02-25 2014-11-26 Kowa Company, Ltd. AGENT PROMOTEUR DE TRANSFERT NUCLEAIRE POUR LA PROTINE Rac ET METHODE POUR LA CRIBLER
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
AU2006204038A1 (en) 2005-01-06 2006-07-13 Merck & Co., Inc. Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
EP1726962A1 (fr) * 2005-05-24 2006-11-29 Leiden University Medical Center Concentrations plasmatiques de lipoprotéine E pour surveiller et réduire le risque des maladies cardiovasculaires
CN101103983B (zh) * 2006-07-14 2012-09-26 海南盛科生命科学研究院 一种用碱试剂稳定的含匹伐他汀钙的药用组合物及制备工艺
EP2170065A4 (fr) 2007-06-20 2011-11-23 Merck Sharp & Dohme Alcanes diphényl-substitués
US8372877B2 (en) 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
CN103153299A (zh) 2010-10-06 2013-06-12 国立大学法人东京大学 淋巴水肿预防治疗剂
WO2012097744A1 (fr) 2011-01-20 2012-07-26 Merck Sharp & Dohme Corp. Antagonistes du récepteur des minéralocorticoïdes
WO2012141160A1 (fr) 2011-04-12 2012-10-18 沢井製薬株式会社 Préparation contenant de la pitavastatine et son procédé de production
WO2012139495A1 (fr) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. Antagonistes des récepteurs de minéralocorticoïdes
WO2012153181A1 (fr) 2011-05-11 2012-11-15 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Composition pharmaceutique comprenant de la pitavastatine ou ses sels pharmaceutiquement acceptables
CN102861018A (zh) * 2011-07-05 2013-01-09 南京长澳医药科技有限公司 一种匹伐他汀钙制剂及其制备工艺
JP5809467B2 (ja) * 2011-07-12 2015-11-11 エルメッド エーザイ株式会社 ピタバスタチン含有組成物及びその製造方法
JP5844574B2 (ja) * 2011-08-10 2016-01-20 共和薬品工業株式会社 ピタバスタチンを含有する安定化された薬物組成物
WO2013055606A1 (fr) 2011-10-13 2013-04-18 Merck Sharp & Dohme Corp. Antagonistes de récepteur des minéralocorticoïdes
KR101461841B1 (ko) 2012-08-08 2014-11-13 코와 가부시키가이샤 의약
CN102885797A (zh) * 2012-10-29 2013-01-23 福州海王福药制药有限公司 一种含匹伐他汀钙的组合物及其制备方法和应用
US9750723B2 (en) 2013-10-31 2017-09-05 Ohio University Prevention and treatment of non-alcoholic fatty liver disease
KR20160147007A (ko) 2014-05-30 2016-12-21 화이자 인코포레이티드 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
JP6648108B2 (ja) 2014-07-18 2020-02-14 オハイオ ユニバーシティー 生物学的シグナル伝達を改変するためのイミダゾール及びチアゾール組成物
CN105343008A (zh) * 2015-12-15 2016-02-24 青岛华之草医药科技有限公司 一种匹伐他汀钙组合物
CN107913257A (zh) * 2016-10-10 2018-04-17 北京阜康仁生物制药科技有限公司 一种包含瑞舒伐他汀钙的药物组合物及其制备方法
JP6937195B2 (ja) * 2017-09-01 2021-09-22 興和株式会社 医薬組成物
WO2023275715A1 (fr) 2021-06-30 2023-01-05 Pfizer Inc. Métabolites de modulateurs sélectifs du récepteur des androgènes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327010C (fr) * 1986-02-13 1994-02-15 Tadashi Makino Compositions pharmaceutiques contenant un compose anti-ulcereux de type benzimidazole et sa production
CA1336714C (fr) * 1987-08-20 1995-08-15 Yoshihiro Fujikawa Mevalonolactone de type quinoleine utilisee comme inhibiteurs de la biosynthese du cholesterol
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
JP3528186B2 (ja) * 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them

Also Published As

Publication number Publication date
CN1137684C (zh) 2004-02-11
PT814782E (pt) 2003-04-30
HUP9903536A3 (en) 2001-06-28
ZA9610792B (en) 1997-07-09
NZ324446A (en) 1999-08-30
FR11C0007I2 (fr) 2012-03-16
EP0814782B1 (fr) 2002-11-27
MX9706389A (es) 1998-08-30
NO973814L (no) 1997-10-13
CZ288545B6 (cs) 2001-07-11
CA2213608C (fr) 2003-07-08
HU227798B1 (en) 2012-03-28
HUP9903536A2 (hu) 2000-03-28
WO1997023200A1 (fr) 1997-07-03
SK116097A3 (en) 1998-03-04
AU1171597A (en) 1997-07-17
TW436294B (en) 2001-05-28
NO973814D0 (no) 1997-08-19
JP3276962B2 (ja) 2002-04-22
JPH11503763A (ja) 1999-03-30
PL186907B1 (pl) 2004-03-31
AU725622B2 (en) 2000-10-19
FR11C0007I1 (fr) 2011-04-22
KR19980702370A (ko) 1998-07-15
SK282991B6 (sk) 2003-01-09
IL121565A (en) 2002-02-10
IL121565A0 (en) 1998-02-08
ES2183023T3 (es) 2003-03-16
CA2213608A1 (fr) 1997-07-03
RU2142790C1 (ru) 1999-12-20
KR100348842B1 (ko) 2002-12-31
DK0814782T3 (da) 2002-12-16
DE122011000014I1 (de) 2011-11-03
UA29513C2 (uk) 2000-11-15
CZ268197A3 (cs) 1998-05-13
NO2011006I1 (no) 2011-06-06
EP0814782A1 (fr) 1998-01-07
DE69625046T2 (de) 2003-04-10
ATE228354T1 (de) 2002-12-15
CN1189098A (zh) 1998-07-29
NO316724B1 (no) 2004-04-19
DE69625046D1 (de) 2003-01-09
NO2011006I2 (no) 2012-10-01
PL321868A1 (en) 1997-12-22

Similar Documents

Publication Publication Date Title
IL121565A0 (en) Pharmaceutical composition stabilized with a basic agent
RU92004564A (ru) Фармацевтические композиции и способ их получения
AU694229B2 (en) A pharmaceutical preparation comprising glucagon
CA2201749A1 (fr) Formulations de solutions d'interferon alpha aqueuses stables
EP0191133A3 (en) Stable salts of sam with polyanions
CA2391076A1 (fr) Solutions contenant de l'epinastine
EP0208519A3 (fr) Composition solubilisée d'un agent pharmaceutique peu soluble
AU2001246623A1 (en) Molecule of pharmaceutical interest comprising at its N-terminal a glutamic acid or a glutamine in the form of an addition salt to an acid
CA2057291A1 (fr) Compositions pharmaceutiques de calcitonine humaine stable
CA2429639A1 (fr) Monohydrate d'azithromycine stable
GR3026209T3 (en) Compositions containing quinolone antibiotics and sulfonate of polystyrol.
IS6654A (is) Stöðugt gabapentín með pH innan stýrðra marka
MY103079A (en) New ophtalmological composition of matter
BG103306A (en) Liquid allendronate compositions
CA2015632A1 (fr) Solutions stables d'un analogue de la rebeccamycine et preparations realisees a partir d'elles
CA2079205A1 (fr) Utilisation de l'acide hyaluronique et de formules pour empecher la restenose arterielle
NZ507407A (en) Stable mitoxantrone solutions
CO5070673A1 (es) Composiciones farmaceuticas en forma de solucion estable que comprenden (1s,4r)-cis-4-(2-amino-6-(ciclopropilamino)-9h -purin-9-il)-2-ciclopenteno-1-metanol, un quelador de metal y un agente endulzante
KR910014122A (ko) 에토포시드-2-디메틸아미노 화합물의 동결건조 제제
CA2288049A1 (fr) Concentre enzymatique
HUP0001866A3 (en) Salts of l-carnitine and alkanoyl-l-carnitine derivatives with 2-aminoethanesulfonic acid and pharmaceutical compositions containing them
ES8403719A1 (es) "un metodo para preparar una suspension acuosa estabilizada de oxendolona".
AU6243094A (en) Stable aqueous acid compositions thickened with polyacrylamide
CA2120045A1 (fr) Utilisation d'acide hyaluronique et de ses derives dans la prevention de la restenose arterielle
ZA989775B (en) Processes for producing 7-isoindoline-quinolone-carboxzlic acid derivative and its intermediate as well as salt of 7-isoindoline- quinolonecarboxylic acid derivative its hydrate and composition comprising the same as active ingredient